Elimination of infectious retroviruses during preparation of immunoglobulins.
Safety concerns for immunoglobulin preparations have led us to study partition/inactivation of two prototype retroviruses, mouse xenotropic type C and lymphadenopathy-associated virus (LAV) of the acquired immunodeficiency syndrome (AIDS), during manufacture and storage of immunoglobulins. Reduction of infectious retrovirus titers were 10(5) to 10(8)-fold through Cohn-Oncley cold ethanol fractionation from plasma to fraction II, 10(3) to 10(5)-fold through incubation at pH 4.0 and another 10(4)-fold through incubation of the purified liquid immunoglobulin preparations at 27 degrees C or 45 degrees C. The results support the clinical and epidemiological evidence that therapeutic immunoglobulin preparations do not transmit AIDS virus.
D000818:Animals; D001793:Blood Preservation; D005591:Chemical Fractionation; D017977:Deltaretrovirus / Q000276:immunology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007074:Immunoglobulin G / Q000302:isolation & purification*; D051379:Mice; D008814:Mice, Inbred NZB; D008908:Mink Cell Focus-Inducing Viruses / Q000276:immunology; D012192:Retroviridae Infections / Q000635:transmission*; D013696:Temperature; D065227:Transfusion Reaction
D007074:Immunoglobulin G